ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "prevention"

  • Abstract Number: 2588 • ACR Convergence 2024

    Examining the Influence of Socioeconomic Status on Osteoarthritis Prevalence and Risk Factors Among New York Residents

    Titilayo Adeniran1, David Cecil2 and Ahinee Amamoo3, 1Hospital for Special Surgery (HSS), New York, NY, 2Samford University, Birmingham, 3Samford University, Birmingham, AL

    Background/Purpose: Osteoarthritis (OA) is a chronic, progressive condition affecting the musculoskeletal system, significantly impacting the quality of life and mobility of millions worldwide. It is…
  • Abstract Number: 0138 • ACR Convergence 2024

    SARS-CoV-2 Vaccine Acceptance, Hesitancy and Uptake in a Cohort of Patients with Inflammatory Rheumatic Diseases (IRD)

    iulia roman1, Xenofon Baraliakos2, Uta Kiltz3, Juergen Braun4 and Ioana Andreica5, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, 4Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, 5Rheumazentrum Ruhrgebiet Herne, Herne, Germany

    Background/Purpose: Vaccine acceptance is important to achieve high vaccination coverage and possibly herd immunity. Related to the evolution of the SARS-CoV-2 pandemic with its socio-political…
  • Abstract Number: 0995 • ACR Convergence 2024

    What Is the Carbon Footprint of Adalimumab Originator and Its Various Biosimilar Drugs?

    Ines Moninot1, ROLAND CHAPURLAT2, Elodie FEURER1, Pierre-Jean Cottinet3, Minh-Quyen Le3 and Aurélie Fontana1, 1Hospices Civils Lyon, Lyon, France, 2INSERM 1033, LYON, France, 3INSA Lyon, Lyon, France

    Background/Purpose: In developed countries, the impact of healthcare systems on the environment is sizeable (roughly 8% of the carbon footprint). So, it is essential to…
  • Abstract Number: 2612 • ACR Convergence 2024

    Two-Week Methotrexate Discontinuation in Autoimmune Rheumatic Diseases Patients Vaccinated with Recombinant Herpes Zoster Vaccine: An Interim Analysis of a Prospective Randomized Phase 4 Study

    Ana Cristina Medeiros-Ribeiro1, Joao de Oliveira2, Nadia Aikawa3, Sandra Pasoto2, Leonard Kupa2, Carla Goncalves Schahin Saad4, Luciana Parente2, ANA PAULA ASSAD2, Eduardo Borba2, Emily Figueiredo Neves Yuki2, Andrea Shimabuco4, Karina Bonfiglioli2, Diogo Domiciano2, Percival Sampaio-Barros4, Andre Franco2, Julio Moraes5, Murillo Dorio2, Claudia Goldenstein-Schainberg2, Henrique Carriço Da Silva2, Lucas Guimarães2, Fernanda Chaer6, Caio Laguna Reis de Carvalho2, Henrique Dalmolin2, Clovis Silva7 and Eloisa Bonfa2, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, 2Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 3Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, 5Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, 6Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Santos, Brazil, 7Rheumatology Division and Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil

    Background/Purpose: Temporary methotrexate (MTX) discontinuation may enhance vaccine immune response, but there are no data for the recombinant zoster vaccine (RZV). This study assessed if…
  • Abstract Number: 0156 • ACR Convergence 2024

    Psoriasis and Psoriatic Arthritis Are Independent Risk Factors for Non-Fatal Cardiovascular Admissions in Transition-Age Young Adults

    Anurag Goel1, Joshua Tanzer2 and Vinit Gilvaz3, 1The Warren Alpert Medical School of Brown University, Providence, RI, 2Lifespan Biostatistics, Epidemiology, Research Design, and Informatics Core, Providence, RI, 3The Warren Alpert Medical School of Brown University, East Providence, RI

    Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated…
  • Abstract Number: 1066 • ACR Convergence 2024

    Development of a Pharmacy-Led Intervention to Improve Osteoporosis Screening in VA Community-Based Outpatient Clinics

    Krista Topalsky1, Lee Arphai2, Mary Ellen Amos2, Amanda Mertz2, Christopher Blum3, Timothy Godbey2, Lori Leonard2, Maya Mattar4, Elizabeth Cable2 and Robert Wenzell2, 1University Hospitals/ Case Western Reserve University, Shaker Heights, OH, 2Cleveland VA Medical Center, Cleveland, OH, 3Cleveland VA Medical Center, Cleveland, 4Louis Stokes VA medical Center, Mayfield Heights, OH

    Background/Purpose: Osteoporosis is a major public health concern in the United States, leading to significant morbidity, mortality, and increased economic burden. Fractures are projected to…
  • Abstract Number: 2672 • ACR Convergence 2024

    Prevention of the Development of Rheumatoid Arthritis by a 1-year Course of Methotrexate in ACPA-negative Arthralgia Patients at Increased Risk for Rheumatoid Arthritis: 4 Year Results of the TREAT EARLIER Trial

    Quirine Dumoulin1, Doortje Krijbolder2, Karen Visser3, Leroy Lard4 and Annette van der Helm-van Mil5, 1Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, 2Leiden University Medical Centre, Leiden, Netherlands, 3Haga Hospital The Hague, Amsterdam, Netherlands, 4Haaglanden Medical Center The Hague, Leidschendam, Netherlands, 5LUMC, Leiden, Zuid-Holland, Netherlands

    Background/Purpose: Currently, prevention possibilities of developing ACPA-negative rheumatoid arthritis (RA) are unknown. Studying this is challenging because many ACPA-negative at-risk individuals have low risk of…
  • Abstract Number: 0207 • ACR Convergence 2024

    Investigation of Delays in Cancer Screening in RA

    Rebecca Brooks1, Cassondra Hulshizer2, Andrew C. Hanson3, Vanessa Kronzer1, John Davis1, Elena Myasoedova1 and Cynthia Crowson1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Utica, MN, 3Mayo Clinic, Rochester

    Background/Purpose: Recent studies have shown that RA patients have increased mortality due to cancer. Despite the increased mortality, few studies have investigated the completion of…
  • Abstract Number: 1075 • ACR Convergence 2024

    Optimizing Herpes Zoster Vaccination in Rheumatoid Arthritis Patients Ages 18-49 Years: A Quality Improvement Approach

    Akhil Sood1, Pegah Jahangiri1, Christy Bill2 and Janice Lin1, 1Stanford University, Palo Alto, CA, 2Stanford Health Care, Palo Alto, CA

    Background/Purpose: Patients with rheumatoid arthritis are at increased risk for Herpes Zoster (HZ) infection, which is associated with increased hospitalizations and healthcare resource utilization. Despite…
  • Abstract Number: 2676 • ACR Convergence 2024

    Timeframe for Initiating Methotrexate and Vaccine Response Against Pneumococcus in Rheumatoid Arthritis: The VACIMRA Study

    Jacques MOREL1, Emmanuelle Dernis2, christian roux3, Christophe Richez4, OLIVIER BROCQ5, Bruno Fautrel6, Carine SALLIOT7, Olivier Vittecoq8, Xavier Mariette9, Frédéric LIOTE10, Slim Lassoued11, Cécile Gaujoux-Viala12, Arnaud Constantin13, MArtin Soubrier14, Valerie Devauchelle15, Vincent Goeb16, Jacques-Eric Gottenberg17, Hubert Marotte18, Annouc Rémy Moulard1, Corinne Merle de Boever1, Héléna Huguet1, Odile Launay19, Florence Galtier1 and Marie Christine Picot1, and F-CRIN networks iREIVAC and CRI-IMMIDIATE, 1CHU and University of Montpellier, Montpellier, France, 2CH LE MANS, LE MANS, Pays de la Loire, France, 3rheumatology department, university Cote d'Azur, nice, France, 4Université de Bordeaux, Bordeaux, France, 5Service de Rhumatologie, centre hospitalier Princesse-Grâce, Monaco, Monaco, 6INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, 7CHU and University of Orléans, Orléans, France, 8CHU and University of Rouen, Rouen, France, 9Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, 10CHU and University of Paris Nord, Paris, France, 11CH of Cahors, Cahors, France, 12CHU Nîmes, Nïmes, Languedoc-Roussillon, France, 13Hôpitaux de Toulouse, Toulouse, France, 14Gabriel-Montpied Hospital, Clermont-ferrand, France, 15UBO, Brest, France, 16CHu and University of Amiens, Ameins, France, 17Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, 18Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, 19Centre d’Investigation Clinique en Vaccinologie (CIC Cochin Pasteur), Hôpital Cochin, Paris, Ile-de-France, France

    Background/Purpose: Pneumococcal vaccination is recommended for patients with chronic inflammatory rheumatism treated with immunosuppressants. Methotrexate (MTX) is the first-line treatment used in rheumatoid arthritis (RA),…
  • Abstract Number: 0239 • ACR Convergence 2024

    Neutralising Antibody Responses to Bivalent SARS-CoV-2 Vaccines and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study

    Hilde S. Ørbo1, Taissa M. Kasahara2, Asia-Sophia Wolf3, Kristin H. Bjørlykke4, Joseph Sexton5, Ingrid Jyssum5, Anne Therese Tveter5, Guri Solum3, Ingrid Fadum Kjønstad3, Andreas Lind6, Veselka Petrova Dimova-Svetoslavova6, Tore K. Kvien7, Jørgen Jahnsen8, Espen A. Haavardsholm1, Ludvig A. Munthe9, Sella A. Provan5, John Torgils Vaage9, Siri Mjaaland3, Kristin K. Jørgensen4, Gunnveig Grødeland9, Silje W. Syversen10 and Guro L. Goll10, 1Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 2University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 3Norwegian Institute of Public Health, Section for Immunology, Oslo, Norway, Oslo, Norway, 4Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, 5Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 6Oslo University Hospital, Department of Microbiology, Oslo, Norway, Oslo, Norway, 7Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 8Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, 9Oslo University Hospital, Department of Immunology, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 10Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Health and Society, Oslo, Norway, Oslo, Norway

    Background/Purpose: The SARS-CoV-2 virus mutates continuously, posing challenges for patients with immune-mediated inflammatory diseases (IMIDs) on tumour necrosis factor inhibitors (TNFi). These patients often have…
  • Abstract Number: 1302 • ACR Convergence 2024

    Physician Knowledge, Attitudes and Perceived Barriers to Recommending the Recombinant Varicella Zoster Vaccine

    cori sutton1, yingxue wang2 and priyanka iyer3, 1UC Irvine, orange, 2UC Irvine, Orange, CA, 3Uc Irvine Medical center, orange

    Background/Purpose: Varicella-zoster virus(VZV) or Shingles infections in immunocompromised individuals can lead to severe complications. Despite availability of the Recombinant Varicella Zoster vaccine(RZV), vaccination rates remain suboptimal. The…
  • Abstract Number: 0248 • ACR Convergence 2024

    Recombinant Herpes Zoster Vaccine in a Large Cohort of Autoimmune Rheumatic Diseases Patients: An Interim Analysis of a Prospective Randomized Phase 4 Study

    Nadia Aikawa1, Ana Cristina Medeiros-Ribeiro2, Sandra Pasoto3, Leonard Kupa3, Luciana Seguro4, ANA PAULA ASSAD3, Eduardo Borba3, Carla Goncalves Schahin Saad4, Emily Figueiredo Neves Yuki3, Danieli Andrade5, Andrea Shimabuco4, Karina Bonfiglioli3, Diogo Domiciano3, Julio Moraes3, Samuel Shinjo4, Percival Sampaio-Barros4, Henrique Giardini3, Joao de Oliveira3, Isabele Antonelli3, Renata Pinheiro3, Thais Bonini3, Marta Lopes6, Clovis Silva7 and Eloisa Bonfa3, 1Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, 2Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, 3Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, 5University of São Paulo, São Paulo, SP, Brazil, 6Infectious Disease Department, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 7Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil

    Background/Purpose: Patients with autoimmune rheumatic diseases (ARDs) are at high risk of herpes zoster (HZ) due to their condition and treatment. The new recombinant vaccine…
  • Abstract Number: 1721 • ACR Convergence 2024

    Recombinant Zoster Vaccine Uptake in US Adults with Rheumatic Disease: A Mixed Methods Analysis

    Justin Gatwood1, Catherine McGuiness2, Marie Yasuda2, Chi-Chang Chen2, Vasudha Gupta3 and Nikita Stempniewicz1, 1GSK, Philadelphia, PA, 2IQVIA, Wayne, PA, 3IQVIA, Durham, NC

    Background/Purpose: Compared to the immunocompetent US population ≥50 years, adults with rheumatic diseases are at increased risk for herpes zoster (HZ). To address this risk,…
  • Abstract Number: 0249 • ACR Convergence 2024

    Real World Evidence on the Safety of the Adjuvanted Recombinant Zoster Vaccine in Patients with Rheumatic Diseases – Preliminary Results from a Prospective Multicenter Observational Greek Study

    Christos Koutsianas1, Anastasia Apanomeritaki2, Evgenia Mavrea1, Niki-Violeta Dimopoulou1, Maria Nitsa1, CHRISTINA TSALAPAKI1, Iro-Ioanna Giannakopoulou2 and Dimitrios Vassilopoulos1, 1Clinical Immunology-Rheumatology Unit, 2nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece, 2Rheumatology Clinic, General Hospital Asklepieio Voulas, Voula, Attiki, Greece

    Background/Purpose: Patients with rheumatic diseases (RD) are at increased risk for herpes zoster (HZ) due to disease -related aberrant immune response, comorbid conditions and anti-rheumatic…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology